A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

BACKGROUND: The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models of glioblastoma. METHODS: Galunisertib (300 mg/day) was given orally 14 days on/14 days off (intermittent dosing). Lom...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Neuro Oncol
Κύριοι συγγραφείς: Brandes, Alba A., Carpentier, Antoine F., Kesari, Santosh, Sepulveda-Sanchez, Juan M., Wheeler, Helen R., Chinot, Olivier, Cher, Lawrence, Steinbach, Joachim P., Capper, David, Specenier, Pol, Rodon, Jordi, Cleverly, Ann, Smith, Claire, Gueorguieva, Ivelina, Miles, Colin, Guba, Susan C., Desaiah, Durisala, Lahn, Michael M., Wick, Wolfgang
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Oxford University Press 2016
Θέματα:
Clinical Investigations
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4933481/
https://ncbi.nlm.nih.gov/pubmed/26902851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now009
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια